Abstract
Synthetic lipopeptides have demonstrated great potential as a vaccine strategy for eliciting cellular and humoral immunity. One of the most potent lipid moieties used is S-[2,3-bis(palmitoyloxy)propyl]cysteine (Pam2Cys). Pam2Cys binds to and activates dendritic cells by engagement of Toll like receptor 2 (TLR 2). In this study, we have investigated the structural requirement of the agonist activity of Pam2Cys by varying the three structural elements of the core structure S-(2,3-dihydroxypropyl)-cysteine namely (1) the α-amino group of the cysteine residue (2) the sulphur atom of the cysteine residue and (3) the 2,3-dihydroxypropyl moiety. Four novel analogues of Pam2Cys were made and each of these analogues were incorporated into vaccine constructs and examined for immunogenicity. Our results demonstrate that (1) the potency of the peptide vaccine is least affected by removal of the amino group (2) substitution of the sulphur atom with an amide bond leads to significant reduction of biological activity (3) removal of the amino group and at the same time substitution of the sulphur with an amide bond significantly decreases the biological activity (4) in the two analogues in which the sulphur atom is replaced with an amide bond the analogue containing the 1,3-dihydroxypropyl moiety demonstrates higher activity than the one which contains 2,3-dihydroxypropyl. In conclusion, the results demonstrate strict structural requirements for agonist activity of the TLR2 ligand Pam2Cys.
Similar content being viewed by others
References
Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Zeng W, Jackson DC, Roden RB (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105:5850–5855
Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF (2006) Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 194:325–330
Baz A, Buttigieg K, Zeng W, Rizkalla M, Jackson DC, Groves P, Kelso A (2008) Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine 26:2570–2579
Belz G, Smith C, Bharadwaj M, Rice A, Jackson D (2004) DCs as targets for vaccine design. Cytotherapy 6:88–98
Borges E, Wiesmuller KH, Jung G, Walden P (1994) Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid. J Immunol Methods 173:253–263
Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, Ulmer AJ (2005a) Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 35:282–289
Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Ulmer AJ (2005b) Lipopeptide structure determines TLR2 dependent cell activation level. Febs J 272:6354–6364
Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, Ulmer AJ (2006) TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 281:9049–9057
Chua BY, Zeng W, Lau YF, Jackson DC (2007) Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 25:92–101
Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ (2007) The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 179:2187–2194
Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, Jackson DC, Brown LE (2006) Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 36:770–778
Heine H, Lien E (2003) Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 130:180–192
Jackson DC, Fitzmaurice C, Sheppard RC, McMurray J, Brown LE (1995) Antigenic and immunogenic properties of synthetic peptide-based T-cell determinant polymers. Biomed Pept Proteins Nucleic Acids 1:171–176
Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 101:15440–15445
Jin MS, Lee JO (2008a) Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182–191
Jin MS, Lee JO (2008b) Structures of TLR-ligand complexes. Curr Opin Immunol 20:414–419
Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130:1071–1082
Jung G, Bessler WG (1995) Lipopeptides as adjuvant and intergratd adjuvanticity. In: Zegers ND, Boersma WJA, Claassen E (eds) Immunological recognition of peptides in medicine and biology. CRC Press, Boca Raton, pp 159–168
Kumagai Y, Takeuchi O, Akira S (2008) Pathogen recognition by innate receptors. J Infect Chemother 14:86–92
Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE (2006) Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18:1801–1813
Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T (2001) Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 166:5161–5167
Metzger J, Jung G, Bessler WG, Hoffmann P, Strecker M, Lieberknecht A, Schmidt U (1991) Lipopeptides containing 2-(palmitoylamino)-6, 7-bis(palmitoyloxy) heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro. J Med Chem 34:1969–1974
Metzger JW, Beck-Sickinger AG, Loleit M, Eckert M, Bessler WG, Jung G (1995) Synthetic S-(2, 3-dihydroxypropyl)-cysteinyl peptides derived from the N-terminus of the cytochrome subunit of the photoreaction centre of Rhodopseudomonas viridis enhance murine splenocyte proliferation. J Pept Sci 1:184–190
Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G (1997) Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185:1951–1958
Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G (1998) Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun 66:4804–4810
Sandor F, Latz E, Re F, Mandell L, Repik G, Golenbock DT, Espevik T, Kurt-Jones EA, Finberg RW (2003) Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling. J Cell Biol 162:1099–1110
Schromm AB, Howe J, Ulmer AJ, Wiesmuller KH, Seyberth T, Jung G, Rossle M, Koch MH, Gutsmann T, Brandenburg K (2007) Physicochemical and biological analysis of synthetic bacterial lipopeptides: validity of the concept of endotoxic conformation. J Biol Chem 282:11030–11037
Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ (1999) Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274:17406–17409
Seyberth T, Voss S, Brock R, Wiesmuller KH, Jung G (2006) Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships. J Med Chem 49:1754–1765
Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, Wiesmuller KH (2004) Synthetic lipopeptide adjuvants and Toll-like receptor 2—structure–activity relationships. Vaccine 22:2494–2499
Takeda K, Takeuchi O, Akira S (2002) Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 8:459–463
Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S (2000) Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 164:554–557
Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R et al (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95:341–349
Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, Zimmermann VS, Davoust J, Ricciardi-Castagnoli P (1997) Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 185:317–328
Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC (2002) Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 169:4905–4912
Zeng W, Gauci S, Ghosh S, Walker J, Jackson DC (2005) Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 23:4427–4435
Zeng W, Pagnon J, Jackson DC (2007) The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol 44:3724–3731
Acknowledgments
This work was supported by grant from the National Health and Medical Research Council of Australia.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zeng, W., Eriksson, E., Chua, B. et al. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 39, 471–480 (2010). https://doi.org/10.1007/s00726-009-0463-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-009-0463-0